Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

NCT01696084 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

309

Enrollment

INDUSTRY

Sponsor class

Conditions

High Risk Acute Myeloid Leukemia

Interventions

DRUG: CPX-351
DRUG: 7+3 (cytarabine and daunorubicin)

Sponsor

Jazz Pharmaceuticals

Collaborators

[object Object]